
Q&A with Christine Baeder, new chair of the generic industry’s AAM
Generic drugs are more often than not the unsung heroes in healthcare, generating billions in savings every year and increasing access to vital new medicines as the brand-name versions come off patent.
Endpoints News connected with the new chair of the generic industry’s Association for Accessible Medicines, Christine Baeder, who is also Teva’s COO, via video conference on Friday.
Baeder explains below not only what’s coming for AAM and its member generic drug companies, but also her thoughts on the Inflation Reduction Act and the new five-year FDA user fee deal. Below is a lightly edited and condensed version of the interview.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters